| Literature DB >> 19410624 |
Ruth D Ellis1, Gregory E D Mullen, Mark Pierce, Laura B Martin, Kazutoyo Miura, Michael P Fay, Carole A Long, Donna Shaffer, Allan Saul, Louis H Miller, Anna P Durbin.
Abstract
A Phase 1 study was conducted in 24 malaria naïve adults to assess the safety and immunogenicity of the recombinant protein vaccine apical membrane antigen 1-Combination 1 (AMA1-C1)/Alhydrogel with CPG 7909 in two different formulations (phosphate buffer and saline), and given at two different dosing schedules, 0 and 1 month or 0 and 2 months. Both formulations were well tolerated and frequency of local reactions and solicited adverse events was similar among the groups. Peak antibody levels in the groups receiving CPG 7909 in saline were not significantly different than those receiving CPG 7909 in phosphate. Peak antibody levels in the groups vaccinated at a 0,2 month interval were 2.52-fold higher than those vaccinated at a 0,1 month interval (p=0.037, 95% CI 1.03, 4.28). In vitro growth inhibition followed the antibody level: median inhibition was 51% (0,1 month interval) versus 85% (0,2 month interval) in antibody from samples taken 2 weeks post-second vaccination (p=0.056).Entities:
Mesh：
Substances：
Year: 2009 PMID： 19410624 PMCID： PMC2722923 DOI： 10.1016/j.vaccine.2009.04.077
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641